Redeye provides a research update after Optomed’s Q1 2026 report. Sales came in below expectations during the quarter, which led to yesterday’s share price decline. The weakness was mainly driven by timing effects, and we expect a rebound in Q2; however, it also introduced some uncertainty around the near-term outlook, prompting us to take a more cautious stance in our sales forecasts, resulting in a lower fair value range.
LÄS MER
